 Delcath Systems Inc NASDAQ: DCTH has announced positive preliminary efficacy results from its FOCUS Phase 3 trial evaluating Hepzato Kit melphalan hydrochloride for injectionhepatic delivery system in patients with liver dominant metastatic ocular melanoma. Data were presented at the American Society of Clinical Oncology Annual Meeting. 